Vacina COVID-19 em pacientes com urticária – Posicionamento do Departamento Científico de Urticária da Associação Brasileira de Alergia e Imunologia (ASBAI)
COVID-19 vaccine in patients with urticaria – Position statement of the Scientific Department of Urticaria of the Brazilian Association of Allergy and Immunology (ASBAI)
Gabriela Andrade Coelho Dias; Leila Vieira Borges Trancoso Neves; Fernanda Lugão Campinhos; Daniela Farah Teixeira Raeder; Larissa Silva Brandão; Régis Albuquerque Campos; Alfeu Tavares França; Rozana F. Gonçalves; Eli Mansour; Janaina Michele Lima Melo; Dirlene Brandão de Almeida Salvador; Solange Oliveira Rodrigues Valle; Carolina Tavares de Alcântara; Rosana Câmara Agondi; Luis Felipe Ensina
Resumo
Com o início do programa de vacinação contra a COVID-19 no Brasil, surgiu uma série de questionamentos relacionados ao uso dos imunizantes em pacientes com doenças imunoalérgicas. Neste documento, o Departamento Científico de Urticária da Associação Brasileira de Alergia e Imunologia (ASBAI) se posiciona revisando as principais dúvidas relacionadas à imunização para COVID-19 em pacientes com urticária.
Palavras-chave
Abstract
As the COVID-19 vaccination program started in Brazil, many questions have arisen regarding the use of vaccines in patients with immune-allergic diseases. In this document, the Scientific Department of Urticaria of the Brazilian Association of Allergy and Immunology takes a stand by reviewing the main queries regarding COVID-19 immunization in patients with urticaria.
Keywords
Referências
1. WHO. COVID-19 Clinical management: living guidance. Geneva: World Health Organization; 2021 [Internet]. Disponível em: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. Acessado em: 30/03/2021.
2. Banerji A, Wickner PG, Saff R, Stone CA Jr, Robinson LB, Long AA, et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. J Allergy Clin Immunol Pract. 2020;9(4):1423-37.
3. Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al. COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization anaphylaxis commitee. World Allergy Organ J. 2021;14(2):100517.
4. Giavina-Bianchi P, Kalil J. May polyethylene glycol be the cause of anaphylaxis to mRNA COVID-19 vaccines? World Allergy Organ J. 2021:100532.
5. Greenhawt M, Abrams EM, Oppenheimer J, Leek TKV, Mack DP, Singer AG, et al. The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World. J Allergy Clin Immunol Pract. 2021;9(4):1438-41.
6. Leek TKV, Chan ES, Connors L, Derfalvi B, Ellis AK, Upton JEM, et al. COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol. 2021;17(1):29.
7. Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al. Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines (Basel). 2021;9(3):221.
8. Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 2020;27(1):104.
9. Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021;222:108634.
10. Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021; Epub ahead of print.
11. CDC COVID-19 Response Team: Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States. MMWR Morb Mortal Wkly Rep. 2021;70(2):46-51.
12. Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda LK, et al. COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organ J. 2020;13(5):100126.
13. Thyssen JP, Vestergaard C, Barbarot S, de Bruin-Weller M, Bieber T, Taieb A, et al. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. J Eur Acad Dermatol Venereol. 2021: 10.1111/jdv.17167.
Submetido em:
19/03/2021
Aceito em:
26/03/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email